Myocardial fas and cytokine expression in end-stage heart failure: Impact of LVAD support

Clinical and Translational Science

Volumn 1, Issue 3, 2008, Pages 245-248

  Bedi, Maninder S ^a   Alvarez Jr , Rene J ^a   Kubota, Toru ^b   Sheppard, Richard ^c   Kormos, Robert L ^a   Siegenthaler, Michael P ^a   Feldman, Arthur M ^d   Mctiernan, Charles F ^a   Mcnamara, Dennis M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c MCGILL UNIVERSITY   (Canada)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Cytokines; Heart failure; Myocardium; Transplantation

Indexed keywords

FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART ASSIST DEVICE; HEART FAILURE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY;

ADULT; AGED; ANTIGENS, CD95; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75449100619     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2008.00056.x     Document Type: Article

References (28)

1. Kubota T, Masayuki M, Alvarez R, Kormos R, Rosenblum W, Demitris A, Semigran M, Dec GW, Holubkov R, McTiernan CF, Mann DL, Feldman AM, McNamara DM. Expression of prointflammatory cytokines in the failing human heart: Comparison of recent onset and end stage heart failure. J Heart Lung Trans. 2000; 19 (9): 819-824.
2. Chen QM, Tu VC. Apoptosis and heart failure. Am J Cardiovasc Drugs. 2002; 2 (1): 43-57.
3. Mann DL. Inflammatory mediators and the failing human heart. Past present and the foreseeable future. Circ Res. 2002; 91: 988-998.
4. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsy W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson RG, Ronan NS, Meier P. Long term use of a left ventricular assist device for end stage heart failure. N Engl J Med. 2001; 345 (20): 1435-1443.
5. DeRose JJ, Argenziano M, Sun BC, Reemtsma k, Oz MC, Rose EA. Implantable left ventricular assist devices: An evolving long term cardiac replacement therapy. Ann Surg. 1997; 226 (4): 461-470.
6. Simon MA, Kormos RL, Murali S, Nair P, Heffernan M, Gorcsan J, Winowich S, McNamara DM. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation. 2005; 112 (9 Suppl): I32-I36.
7. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw B-A. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996; 335: 1182-1189.
8. Birks EJ, Latif N, Owen V, Bowles C, Felkin LE, Mullen AJ, Khaghani A, Barton PJR, Polak JM, Pepper JR, Banner NR, Yacoub MH. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation. 2001; 104 (12 Suppl): I233-I240.
9. Bennet MR. Apoptosis in the cardiovascular system. Heart. 2002; 87 (5): 480-487.
10. Marshall D, Sack MN. Apoptosis: A pivotal event or an epiphenomenon in the pathophysiology of heart failure. Heart. 2000; 84 (4): 355-356.
11. Schumann H, Moraweitz H, Hakim K, Zerkowski HR, Holtz J, Darmer D. Alternative splicing of the primary Fas transcript in the failing ventricular myocardium. Biochem Biophys Res Commun. 1997; 239 (3): 794-798.
12. Valgimigli M, Curello S, Ceconi C, Agnolett L, Comini L, Bachetti T, Merli E, Ferrari R. Neurohormones, cytokines, and programmed cell death in heart failure. Cardiovasc Drugs Ther. 2001; 15: 529-537.
13. Wollert KC, Heineke J, Westermann J, Ludde M, Fiedler B, Zeirhut W, Laurent D, Bauer MK, Schulze-Osthoff K, Drexler H. The cardiac FAS (APO1/ CD95) receptor/FAS ligand system: Relation to diastolic wall stress in volume overload hypertrophy in vivo and activation of the transcription factor AP1 in cardiac myocytes. Circulation. 2000; 101 (10): 1172-1178.
14. Yamaguchi S, Yamaoka M, Okuyama M, Nitoube J, Fukui A, Shirakabe M, Shirakawa K, Nakamura N, Tomoike H. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol. 1999; 83: 1500-1503.
15. Blum A, Miller H. Role of cytokines in heart failure. Am Heart J. 1998; 135: 181-186.
16. Satoh M, Nakamura M, Tamura G, Makita S, Segawa I, Tashiro A, Satodate R, Hiramori K. Inducible nitric oxide synthase and tumor necrosis factor alpha in human dilated cardiomyopathy. J Am Coll Cardiol. 1997; 39: 716-724.
17. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. J Am Coll Cardiol. 1997; 79: 1128-1131.
18. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and function of TNF receptors in the human myocardium. Circulation. 1995; 92: 1487-1493.
19. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL. Soluble tumor necrosis factor proteins modulate the negative inotropic effect of TNF alpha in vitro. Am J Physiol. 1995; 37: H517-H525.
20. Sheppard R, Bedi M, Kubota T, Semigran MJ, Dec W, Holubkov R, Feldman AM, Rosenblum WD, McTiernan CF, McNamara DM; IMAC investigators. Myocardial expression of Fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol. 2005; 46 (6): 1036-1042.
21. Torre-Amione G, Stetson S, Youker K, Durand J, Radovancevic B, Delgado RM, Frazier OH, Entman ML, Noon G. Decreased expression of tumor necrosis factor-a in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery. Circulation. 1999; 100 (11): 1189-1193.
22. Razeghi P, Mukhopadhyay M, Myers TJ, Williams JN, Moravec CS, Fraizier OH, Taegtmeyer H. Myocardial tumor necrosis factor-alpha expression does not correlate with indices of heart failure in patients on left ventricular device support. Ann Thorac Surg. 2001; 72 (6): 2044-2050.
23. Hall JL, Birks EJ, Grindle S, Cullen ME, Barton PJ, Rider JE, Lee S, Harwalker S, Mariash A, Adhikari N, Charles NJ, Felkin LE, Polster S, George RS, Miller LW, Yacoub MH. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur Heart J. 2007; 28 (5): 522-524.
24. Birks EJ, Hall JL, Barton PJ, Grindle S, Latif N, Hardy J P, Rider JE, Banner NR, Khaghani A, Miller LW, Yacoub MH. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation. 2005; 112 (9 Suppl): I57-I64.
25. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, Torre-Amione G, for the LVAD Working Group. Cardiac improvement during mechanical circulatory support: A prospective multicenter study of the LVAD Working Group. Circulation. 2007; 115 (19): 2497-2505.
26. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006; 355 (18): 1873-1884.
27. Skudicky D, Sliwa K, Bergermann A, et al. Reduction in the FAS/APO-1 plasma levels correlate with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxyphyline. Heart. 2000; 84: 438.
28. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001; 103 (8): 1044-1047.